

Aurealis Pharma Expands its Management Team and Announces Opening of New Office In Basel Switzerland

Kuopio Finland, Basel Switzerland – September 4th 2015.

Aurealis Pharma, a privately owned biopharmaceutical company focused on developing innovative treatment options for patients with chronic inflammation and cancer, announced today the opening of new office in Basel Switzerland and the appointment of Dr. Dirk Weber, MD as a Chief Medical Officer (CMO).

The Basel office will support the growth and development of Aurealis Pharma by providing access to the extensive experience in Life Science business and resources available in the region. The new facility and appointment of Dr. Dirk Weber as a CMO serves to strengthen Aurealis Pharma presence in Switzerland and leverage collaboration and communication to investors, pharma and biotech as well as to facilitate the development path of our products into the clinics.

Dr Weber is an MD, PhD with 12+ years of Pharma industry experience in global oncology drug development from leadership positions at Merck Serono, Novartis Pharma and Takeda Pharmaceuticals where he was recently Medical Director hemato-oncology/oncology. He has worked in early- and late-stage clinical development programs which included interactions with all major regulatory authorities, dossier filing and lead of a submission team. He also has extensive experience in conducting Medical Affairs activities to prepare markets and position products successfully for commercial launches.

“The opening of the Basel office and having such an experienced pharma expert as Dirk onboard is an exciting milestone for Aurealis Pharma” said CEO Juha Yrjänheikki. “There is a significant opportunity for growth and collaboration in Basel, the major global hub of pharma and biotech. We are committed to continuously improving our business in this region to support these aspirations.”

“I am excited to be appointed as CMO for Aurealis Pharma at this important time in the company’s evolution as we prepare to advance development of our platform technology and lead product AUP-16 for treatment of diabetic foot ulcers towards its clinical use,” said Dirk Weber. “I look forward to contributing my skills to the impressive progress made to date by the Aurealis team in advancing our technology and pipeline with the potential to provide new and better treatment options to our patients at need.

Aurealis Pharma is a Kuopio Finland and Basel Switzerland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in



AUREALIS PHARMA

Microkatu 1 Greifengasse 11
FI-70210 Kuopio CH-4058 Basel
Finland Switzerland
www.aurealispharma.com

chronic inflammation and cancer. Company's technology is based on safe food-grade lactic acid bacteria delivering and secreting multiple human therapeutic proteins in target tissue facilitating protein/antibody combination therapy in a single product to address the unmet medical need in patients with severe diseases like chronic wound ulcers and malignant and invasive cancer indications.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA

Microkatu 1

FI-70210 Kuopio

Finland

Greifengasse 11

CH-4058 Basel

Switzerland

www.aurealispharma.com